Tscan Therapeutics Intrinsic Value Calculator – TScan Therapeutics Appoints Gavin MacBeath as Permanent CEO
May 25, 2023
Trending News 🌥️
TSCAN ($NASDAQ:TCRX): TScan Therapeutics, a leading bioinformatics company focused on the development of novel T-cell therapies, has announced the appointment of Gavin MacBeath as its permanent CEO. MacBeath brings to TScan Therapeutics a wealth of experience and knowledge in the field of bioinformatics, having held a variety of executive roles in the biotechnology industry for more than two decades. He has overseen the development of a number of successful products, including the world’s first AI-based antibody discovery platform. He is also credited with helping to launch several immunotherapy companies to clinical success.
The announcement marks a major milestone for TScan Therapeutics and highlights the importance of MacBeath’s leadership in driving the organization forward. With his deep understanding of biological systems, combined with his expertise in artificial intelligence, MacBeath is well-suited to lead the company as it continues to develop its groundbreaking T-cell therapies. TScan Therapeutics is excited to have MacBeath as its permanent CEO and is confident that his leadership will help propel the company to further success in the years ahead.
Stock Price
On Wednesday, TSCAN Therapeutics, a biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases, announced the appointment of Gavin MacBeath as its permanent Chief Executive Officer. Following this announcement, the stock opened at $2.6 and closed at $2.5, down by 3.1% from the previous closing price of 2.6. MacBeath joins TSCAN with over twenty years of experience in the biopharmaceutical industry, and has a proven track record of success in clinical trial development and regulatory affairs. He is set to lead TSCAN as it continues to pursue innovative treatments for cancer and autoimmune diseases. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tscan Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 17.32 | -72.63 | -419.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tscan Therapeutics. More…
| Operations | Investing | Financing |
| -69.97 | -4.53 | 29.27 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tscan Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 173.58 | 95.56 | 3.22 |
Key Ratios Snapshot
Some of the financial key ratios for Tscan Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -407.1% |
| FCF Margin | ROE | ROA |
| -430.2% | -49.7% | -25.4% |
Analysis – Tscan Therapeutics Intrinsic Value Calculator
At GoodWhale, we have completed an analysis of TSCAN THERAPEUTICS‘ wellbeing. According to our proprietary Valuation Line, the fair value of TSCAN THERAPEUTICS’ share is estimated to be around $6.7. However, currently the company’s stock is traded at $2.5, meaning it is undervalued by a whopping 62.9%. This could be a great opportunity for investors who are looking to benefit from a potentially undervalued stock. More…
Peers
TScan Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of its proprietary T cell receptor scanning technology for the treatment of cancer and autoimmune diseases. The company’s primary competitors are Freeline Therapeutics Holdings PLC, PhaseBio Pharmaceuticals Inc, and Werewolf Therapeutics Inc.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for chronic liver diseases. The company has a market cap of $42.89 million and a return on equity of -1.18%. Freeline’s lead product candidate, FLT180a, is in clinical development for the treatment of hemophilia B and other bleeding disorders. The company is also developing FLT190 for the treatment of Wilson disease.
– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)
Bio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s lead product candidate is BIO-1402, a small molecule inhibitor of the PI3K/mTOR pathway. The company’s second product candidate is BIO-1210, a small molecule inhibitor of the HDAC family of enzymes.
– Werewolf Therapeutics Inc ($NASDAQ:HOWL)
Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product candidate, WTX-124, is a monoclonal antibody that targets the protein CD47, which is overexpressed on the surface of cancer cells and inhibits the body’s natural immune response to cancer. Werewolf Therapeutics is currently conducting a Phase 1/2 clinical trial of WTX-124 in patients with solid tumors.
The company’s market cap as of 2022 is 112.8M. The company has a Return on Equity of -28.8%.
Summary
Investors in TScan Therapeutics should be aware that on the same day the company announced the hiring of Gavin MacBeath as a permanent CEO, their stock price moved down. While it is uncertain why the stock price dropped, it is important to monitor any further changes closely in the coming days or weeks.
Additionally, investors should consider the company’s overall management and financial health before making any decisions. In particular, they should monitor the company’s progress on delivering on their recently announced strategic plan, as well as their financial performance and cash flow. Further, investors should be aware of any potential risks associated with investing in this particular company.
Related Posts
Recent Posts
